Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists

A kind of methylpyrrolidine, methoxyl technology, applied in (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methyl Crystalline form of pyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonist It can solve problems such as prevention and effective treatment that have not yet appeared

Active Publication Date: 2016-07-20
IDORSIA PHARM LTD
View PDF44 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Indeed, memory loss or impairment of memory acquisition is a prominent feature of such disorders, and no effective therapy exists to prevent this adverse process

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
  • Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
  • Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0159] Preparative HPLC for Purification of Compounds (Condition C)

[0160] Column: WatersXBridge (10 μm, 75×30 mm). Conditions: MeCN [eluent A]; water + 0.5% NH 4 OH (25% aq.) [eluent B]; Gradient: 90% B→5% B over 6.5 min. (Flow rate: 75ml / min). Detection: UV+ELSD.

[0161] Preparative HPLC for Purification of Compounds (Condition D)

[0162] Column: Waters Atlantis T3OBD (10 μm, 75×30 mm). Conditions: MeCN [eluent A]; water + 0.5% HCOOH [eluent B]; gradient: 90% B→5% B over 6.4 min. (Flow rate: 75ml / min). Detection: UV+ELSD.

[0163] LC-MS under acidic conditions

[0164] Device: Agilent 1100 series with mass spectrometry detection (MS: Finnigan single quadrupole). Column: Agilent Zorbax SB-Aq, (3.5 μm, 4.6×50mm). Conditions: MeCN [eluent A]; water+0.04% TFA [eluent B]. Gradient: 95% B → 5% B over 1.5 min. (Flow rate: 4.5ml / min). Detection: UV+MS.

[0165] X-ray powder diffraction (XRPD) analysis

[0166] In having the CuK a - X-ray powder diffraction patter...

example 1

[0195] Example 1: Preparation and Characterization of Compounds in Form 1

[0196] a) Preparation of Seed Material of Compound in Form 1

[0197] In a 7 mL vial, 0.2 g of the compound as an amorphous mass was dissolved in 2 mL of MeOH. Samples were left open at ambient and evaporated over the weekend. Amorphous lumps with some crystals were obtained as observed under crossed polarizers. 0.05 mL of MeOH was added, the vial was closed and the sample was sonicated for 1 min and heated to 40°C. This procedure was repeated 3 to 4 times to cause further crystallization and after about 15 min the sample was further shaken at 25°C for 1 h. Thereafter the solid was isolated, dried under reduced pressure (2 mbar, room temperature) for 4 hours and allowed to equilibrate open at room temperature and 58% relative humidity for 2 hours. An off-white powder was obtained as the compound in Form 1. It may be necessary to repeat this procedure several times to obtain sufficient material for...

example 2

[0203] Example 2: Preparation and Characterization of Compounds in Form 2

[0204] 0.05 mL of acetonitrile was mixed with 0.01 g of the compound in Form 1 in a 4 mL glass with a magnetic stirrer for 3 days at room temperature. The solid was isolated and dried under reduced pressure (2 mbar for 30 min) and was the compound in Form 2.

[0205] Alternatively, 0.1 mL of methyl-isobutyl ketone was mixed with 0.015 g of the compound in Form 1 in a 4 mL glass with a magnetic stirrer for up to 3 days at room temperature. The solid was isolated and dried under reduced pressure (2 h at 2 mbar) and was the compound in Form 2.

[0206] Table 3: Characterization data for the compound in Form 2

[0207]

[0208] III. Bioanalysis

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
Login to View More

Abstract

The invention relates to crystalline forms of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2- yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone, processes for the preparation thereof, pharmaceutical compositions containing such crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as orexin receptor antagonists.

Description

technical field [0001] The present invention relates to a kind of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5- Novel crystal form of methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone (hereinafter also referred to as "compound"), process for its preparation, medicine comprising such crystal form Compositions, pharmaceutical compositions prepared from such crystalline forms and their use as orexin receptor antagonists in the treatment or prevention of sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunction, mood disorders or appetite disorders. Background technique [0002] Orexin (orexin A or OX-A and orexin B or OX-B) are neuropeptides discovered by two research groups in 1998, orexin A is a 33 amino acid peptide and orexin B is a 28 amino acid peptide (SakuraiT et al., Cell, 1998, 92, 573-585). Orexin is produced in discrete neurons in the lateral hypothalamus and binds to G protein-coupled receptors (OX 1 and OX ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D403/14A61K31/4192A61P25/00
CPCC07D403/14A61P25/00A61P25/20A61P25/22A61P25/24A61P25/28A61K31/4192C07B2200/13
Inventor 克里斯托弗·博斯克莉丝汀·普罗奇马库斯·古德比比亚·海德曼蒂埃里·西弗朗马库斯·冯劳默尔约迪·T·威廉斯
Owner IDORSIA PHARM LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com